A preprint of the study by researchers of Oxford University noted that a third dose of the AstraZeneca vaccine will also lead to a substantial increase in immune response.
UK’s drug regulator is investigating rare cases of blood clots in adults who were given Oxford-AstraZeneca shot. No safety issues have arisen in children’s trial, Oxford says.
In a letter to the Serum Institute, Drugs Controller General of India Somani said the institute is permitted to apply the shelf life of 9 months to unlabeled vials available on hand.
Amid reports that doses were causing blood clot-related complications, Johnson said that six months since its discovery, multiple countries like India are producing the vaccine.
According to Oxford University researchers, the first dose of the vaccine offers 76% protection, making it safe for the interval between doses to be extended to 3 months.
India’s vaccination strategy is smartly-designed and will strengthen healthcare workers to handle a second wave, says Dr V. Ravi, former basic sciences dean at NIMHANS.
From Munir’s point of view, a few bumps here and there is par for the course. He isn’t going to drive his dumper truck to its doom. He wants to use it as a weapon.
COMMENTS